ClinicalTrials.gg
CompletedNCT04806295Updated Nov 18, 2026

The Leukemia and Lymphoma Society (LLS) National Research Registry

An observational study in Blood Cancer, sponsored by Blood Cancer United. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Blood Cancer United · Observational

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,200
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
29th of 157
1,200 · median 150
Started
2017
with 36 others
Observational
157 of 823
56 open now
Registered
583rd of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 29th largest by enrollment of the 157 observational ones that give a count, is one of 37 that started in 2017, is one of 157 observational ones, and was the 583rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

Read the detailed description

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment.

The LLS National Research Registry Protocol will:

  1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data.
  2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly.
  3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed.
  4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information.
03

Conditions studied

  • Blood Cancer
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with blood cancer, before, during, and after blood cancer treatments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

People with blood cancer, before, during, and after blood cancer treatments.

Exclusion criteria

Exclusion Criteria:

People unable or unwilling to sign .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,200 participants (actual)
Patient registry
No

Interventions

  • Otherany/all treatments for blood cancer

    Following people undergoing any/all treatments for blood cancer.

06

What researchers measure

Primary outcomes

  1. LLS will monitor outcomes of people being treated for blood cancer.

    . The LLS National Research Registry will collect data on up to 1000 research subjects, over up to 10 years, storing that data, including protected health information (PHI) and images, in secure databases, and share de-identified summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. Participation in The LLS National Research Registry may not give research subjects any immediate benefit. It is hoped the knowledge gained from data collected in The LLS National Research Registry will benefit people with blood cancers in the future using this information for research purposes, directed at blood cancers and associated comorbidities.

    Time frame: 10 years

07

Study locations

1 site
  • Lymphoma and Leukemia Society
    Rye Brook, New York 10573, United States
08

References and documents

Individual participant data

Plan to share: Yes — Participating subjects will be asked to provide permission to share de-identified summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for cancer, neurological disorders, and other diseases. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed.

Supporting information: Study protocol

Time frame: As data is collected, de-identified and stored in a secure database, it will be provided over time to LLS investigators and investigators approved by LLS.

Access criteria: De-identified data will be made available to LLS investigators and investigators approved by LLS.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2017 to primary completion in Jul 2024, 83 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jul 2027 → Jul 2024 and completion Jul 2027 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 19, 2021
StartActual
Jul 24, 2017
Primary completionActual
Jul 23, 2024was Jul 2027
CompletionActual
Jul 23, 2024was Jul 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Primary completion
Jul 23, 2027→Jul 23, 2024 (actual)
Nov 18, 2026
Study completion
Jul 23, 2027→Jul 23, 2024 (actual)
Nov 18, 2026
Enrollment
1000 (estimated)→1200 (actual)
Nov 18, 2026
Sponsor
Lymphoma and Leukemia Society→Blood Cancer United
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion Jul 23, 2027→Jul 23, 2024 (now actual)
    Study completion Jul 23, 2027→Jul 23, 2024 (now actual)
    Enrollment 1000 (estimated)→1200 (actual)
    Sponsor Lymphoma and Leukemia Society→Blood Cancer United
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04806295
Lead sponsor
Blood Cancer United
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Jul 24, 2017
Primary completion
Jul 23, 2024
Completion
Jul 23, 2024
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion